Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TechnologyAdvice

- PMLiVE

Japan first to approve Novartis psoriasis drug Cosentyx

Becomes first company to gain approval for an interleukin-17 inhibitor

- PMLiVE

Pfizer’s Dr Simon Campbell recognised in UK’s New Year Honours

Recipients also include NICE’s Professor Carole Longson

- PMLiVE

Turkey: A growing pharma market with huge potential

The Turkish biopharma market offers many opportunities - if it can overcome its sustainability challenge

- PMLiVE

Celgene promotes senior EMEA figures

Marie-France Tschudin and Stefano Portolano take on new roles

- PMLiVE

FDA approval for Novo Nordisk’s obesity shot

New formulation of diabetes drug Victoza will be marketed as Saxenda

- PMLiVE

EMA picks projects for adaptive licensing project

Begins discussions on how the model will be implemented in practice

Astellas forges $675m muscle alliance with Cytokinetics

Extendscollaboration to include neuromuscular diseases

NICE rejection of three ovarian cancer drugs stands

Agency will still not recommend Gemzar, Hycamtin and Yondelis for the disease

- PMLiVE

Media planning on a global scale

Think international when combining the most appropriate media vehicles and formats for marketing efforts

- PMLiVE

Assessing drugs for ultra-rare conditions in the UK

Alexion’s Soliris has become the first drug to pass through NICE’s new highly specialised technology process

Bone Therapeutics looks to Pfizer for clinical head

Guy Heynen has 35 years of industry experience

- PMLiVE

BioCryst gets FDA nod for first intravenous flu drug

Expects to launch Rapivab in time for this year's flu season

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links